Apyx Medical Q4 2024 revenue $14.2M (down 3% YoY); net loss narrows to $4.6M; submits AYON 510(k) ahead of schedule

Apyx Medical Corp

Q4 total revenue $14.2M (-3% YoY); Advanced Energy flat at $12.1M. Full year revenue $48.1M (-8%).
Net loss Q4 $4.6M ($0.12 per share) vs $9.6M loss in Q4 2023; adjusted EBITDA loss $2.2M vs $4.7M.
Full year 2024 net loss $23.5M ($0.66 per share) vs $18.7M; adjusted EBITDA loss $14.3M vs $13.4M.
Submitted 510(k) for AYON Body Contouring System ~90 days early; planned launch back half 2025 pending clearance.
Cost restructuring: workforce reduced ~25%, annual savings ~$4.3M. 2025 guidance: revenue $47.6-49.0M, opEx <$40M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.